Open Orphan Plc (HVO) AI Stock Analysis

• Market Cap: £44.66M
• Dividend Yield: 3.05%
• Average Volume (3M): 2.63M
• Price to Earnings (P/E): 4.1
• Beta (1Y): -0.24
• Revenue Growth: 11.92%
• EPS Growth: -33.76%
• Country: UK
• Employees: 301
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): <0.01
• Shares Outstanding: 687,014,100
• 10 Day Avg. Volume: 1,747,209
• 30 Day Avg. Volume: 2,631,178
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £25.00
• Price Target Upside: 252.11% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -0.58
• Revenue Forecast (FY): £3.60B

• Rating: 64 Neutral
• Price Target: 7.50p ▲(5.63% Upside)

Open Orphan Plc's stock score is primarily driven by its strong financial performance and attractive valuation. However, technical indicators suggest bearish momentum, which could pose a risk to short-term price movements. The lack of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates expanding market demand for Open Orphan's services, enhancing its competitive position and long-term viability.

Market Position

Specialization in human challenge studies positions Open Orphan as a leader in a niche market, providing a competitive edge and potential for sustained demand.

Balance Sheet Health

A strong equity position with low leverage enhances financial stability, providing resilience against economic fluctuations and supporting future growth.

Negative Factors

Cash Flow Management

Decreasing operating cash flow may constrain the company's ability to fund operations and growth initiatives, potentially impacting long-term sustainability.

Earnings Volatility

Negative EPS growth suggests earnings volatility, which can undermine investor confidence and affect the company's ability to attract capital for expansion.

Profit Margin Decline

A decline in net profit margin may indicate rising costs or pricing pressures, which could erode profitability if not managed effectively over time.

Open Orphan Plc Business Overview & Revenue Model

Company Description

hVIVO plc (Ticker: HVO) is full-service early phase Contract Research Organisation (CRO) and the global leader in human challenge trials. The company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world's ten largest biopharma companies. hVIVO specialises in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its state-of-the-art quarantine facility in London-the largest of its kind worldwide. The Company also offers comprehensive virology and immunology laboratory services under the hLAB brand. Through its German subsidiary, CRS, hVIVO operates a 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. Its second subsidiary, Venn Life Sciences, offers Early Drug Development Consulting and Biometry services to the biopharma sector. The Group provides fully integrated drug development solutions from preclinical stages through Phase II trials, alongside patient recruitment via FluCamp. Additionally, its five clinical sites support outpatient Phase II and III trials, ensuring a seamless and efficient pathway from discovery to late-stage development.

How the Company Makes Money

Open Orphan generates revenue primarily through its clinical trial services, particularly by conducting human challenge studies for pharmaceutical and biotechnology companies. The company charges clients for the design, execution, and management of these trials, which can be substantial due to the specialized nature of the services provided. Additionally, Open Orphan may earn revenue from partnerships with other research organizations and pharmaceutical companies, including collaborations that allow them to share resources or co-develop products. The company also benefits from grants and funding from governmental and non-governmental organizations focused on public health and infectious disease research, further contributing to its financial stability.

Open Orphan Plc Financial Statement Overview

Summary

Open Orphan Plc demonstrates strong growth and profitability in the biotechnology sector. The income statement highlights robust revenue and profit growth, while the balance sheet shows financial stability with low leverage. However, cash flow management could be improved to ensure sustainable long-term growth. Continued focus on operational efficiency and cash flow generation will be crucial for future success.

Income Statement

The company shows strong revenue growth, with a significant increase from 2023 to 2024. The gross profit margin is very high as cost of goods sold is minimal or zero. The net profit margin is robust, reflecting effective cost management, although it has slightly decreased from the previous year. The EBIT and EBITDA margins show healthy operating profitability, indicating improved operational efficiency.

Balance Sheet

The balance sheet reflects a strong equity position with a solid equity ratio. The debt-to-equity ratio remains low, indicating a conservative leverage stance. Return on equity is positive, showcasing effective use of shareholder funds, although there is room for improvement in leveraging equity to generate higher returns.

Cash Flow

Operating cash flow is positive, but has decreased compared to the previous year. The free cash flow to net income ratio suggests efficient cash generation relative to net income, although free cash flow has declined. The company needs to focus on maintaining healthy cash flow to support operations and growth.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	62.73M	56.04M	48.48M	36.86M	20.60M
Gross Profit	62.73M	10.41M	4.00M	35.90M	19.88M
EBITDA	17.80M	14.02M	9.77M	3.07M	-8.55M
Net Income	10.65M	16.11M	-776.00K	-74.00K	-10.79M
Balance Sheet
Total Assets	88.89M	83.23M	51.38M	42.27M	48.55M
Cash, Cash Equivalents and Short-Term Investments	44.18M	36.97M	28.44M	15.69M	19.20M
Total Debt	12.90M	12.53M	1.56M	3.15M	4.80M
Total Liabilities	44.22M	48.90M	31.16M	21.59M	26.25M
Stockholders Equity	44.67M	34.33M	20.22M	20.68M	22.30M
Cash Flow
Free Cash Flow	7.88M	12.06M	14.62M	-2.30M	3.08M
Operating Cash Flow	10.34M	17.24M	15.98M	-1.56M	4.17M
Investing Cash Flow	-660.00K	-5.18M	-1.36M	-739.00K	1.18M
Financing Cash Flow	-2.40M	-4.70M	-1.83M	-1.20M	13.04M

Open Orphan Plc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:HVO, the sentiment is Negative. The current price of 7.1 is above the 20-day moving average (MA) of 6.92, below the 50-day MA of 8.09, and below the 200-day MA of 12.60, indicating a bearish trend. The MACD of -0.42 indicates Negative momentum. The RSI at 31.82 is Neutral, neither overbought nor oversold. The STOCH value of 20.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:HVO.

Open Orphan Plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HVO	64 Neutral	£44.66M	4.14	―	3.05%	11.92%	-33.76%
AVCT	53 Neutral	£309.91M	―	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SCLP	46 Neutral	£102.22M	-7.46	―	―	―	-94.12%
OBI	41 Neutral	£67.39M	―	―	―	63.25%	8.94%
SBTX	40 Underperform	£41.73M	-12.90	―	―	1557.07%	24.70%
4BB	39 Underperform	£121.56M	-7.90	-209.34%	―	198.49%	-26.66%

Open Orphan Plc Corporate Events

hVIVO Reports Interim Results and Eyes Growth in 2026

hVIVO plc reported its interim results for the first half of 2025, showing a revenue of £24.2 million, in line with expectations for the full year. Despite a decrease in revenue and EBITDA compared to the previous year, the company is optimistic about returning to growth in 2026. The integration of recent acquisitions, CRS and Cryostore, is nearing completion, with sales synergies being realized. The company has signed significant contracts, including a £3.2 million hLAB contract and a letter of intent for a major Phase III human challenge trial. hVIVO’s diversification strategy is showing early success, with a strong sales pipeline and new service lines contributing to future growth prospects. The company expects to achieve high-single digit revenue growth in 2026 as market conditions normalize.

The most recent analyst rating on (GB:HVO) stock is a Buy with a £11.50 price target. To see the full list of analyst forecasts on Open Orphan Plc stock, see the GB:HVO Stock Forecast page.

hVIVO to Release Interim Results and Host Investor Presentation

hVIVO plc announced it will release its interim results for the first half of 2025 on 23 September 2025. The company will hold a briefing for equity research analysts and a live investor presentation on the same day, allowing stakeholders to engage with the company’s leadership. This announcement underscores hVIVO’s commitment to transparency and engagement with its investors, potentially impacting its market position positively.

The most recent analyst rating on (GB:HVO) stock is a Buy with a £11.50 price target. To see the full list of analyst forecasts on Open Orphan Plc stock, see the GB:HVO Stock Forecast page.

hVIVO Appoints Shaun Chilton as Non-Executive Chair to Drive Growth

hVIVO plc has appointed Shaun Chilton as the new Non-Executive Chair of its Board of Directors, effective immediately. Shaun Chilton, who brings over 30 years of experience in leading and managing both private and public businesses, is expected to support hVIVO in its growth and diversification strategy. His previous roles include CEO of Clinigen Group plc and various board positions in UK public companies. This appointment is seen as a strategic move to enhance hVIVO’s leadership as it continues to expand its service offerings and maintain its position as a leader in human challenge trials.

The most recent analyst rating on (GB:HVO) stock is a Buy with a £11.50 price target. To see the full list of analyst forecasts on Open Orphan Plc stock, see the GB:HVO Stock Forecast page.

hVIVO Appoints Shaun Chilton as Non-Executive Chair

hVIVO plc has announced the proposed appointment of Shaun Chilton as Non-Executive Chair, pending customary due diligence. Chilton brings over 30 years of experience in leading both private and public businesses, with a strong track record in sales growth and enterprise value. His appointment is expected to enhance hVIVO’s board with his extensive sector-relevant expertise, potentially impacting the company’s strategic direction and market positioning.

The most recent analyst rating on (GB:HVO) stock is a Buy with a £35.00 price target. To see the full list of analyst forecasts on Open Orphan Plc stock, see the GB:HVO Stock Forecast page.